Thalidomide Helps Refractory UC Patients Achieve and Maintain Remission

Thalidomide Helps Refractory UC Patients Achieve and Maintain Remission
Results from an 8-week clinical trial coupled with an 8-week trial extension show evidence that children with refractory ulcerative colitis (UC) can achieve and maintain remission when treated with the small molecule drug thalidomide. The trial, a pilot effort from multiple medical centers in Italy, evaluated 26 children treated with either thalidomide or placebo. The

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *